Targeting stem cells-clinical implications for cancer therapy

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Molecular Oncology

Background:

• Cancer stem cells (CSCs), or tumor-initiating cells (TICs), are implicated in tumor initiation, progression, and therapeutic resistance.
• Identifying CSCs and their regulatory pathways is crucial for developing effective cancer treatments.
• Existing CSC markers like CD44 and CD133 require complementary markers for precise identification.

Purpose of the Study:

• To review recent advancements in understanding cancer stem cell biology, focusing on brain and intestinal tumors.
• To highlight the role of the PTEN-Akt-Wnt pathway in regulating CSC self-renewal, differentiation, and therapeutic resistance.
• To explore the potential of CSC pathway components as biomarkers for cancer diagnosis, prognosis, and treatment.

Main Methods:

• Literature review of recent studies on cancer stem cells, particularly in brain and intestinal tissues.
• Focus on the molecular mechanisms of the PTEN-Akt-Wnt signaling pathway in CSCs.
• Analysis of CSC markers and their therapeutic implications.

Main Results:

• The PTEN/PI3 kinase pathway plays a critical role in regulating TIC in leukemia, brain, and intestinal tissues.
• The PTEN-Akt-Wnt pathway is central to CSC self-renewal, differentiation, and resistance to therapy.
• New CSC markers and pathway insights are emerging for clinical applications.

Conclusions:

• Understanding CSC molecular mechanisms, especially the PTEN-Akt-Wnt pathway, is vital for eradicating tumors.
• CSC pathway components show promise as biomarkers for cancer diagnosis, prognosis, and targeted therapies.
• Targeting CSCs represents a critical strategy for improving patient survival outcomes.